Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 1/2020

01-03-2020 | Candidiasis | Psoriasis (J Wu, Section Editor)

Bimekizumab

Authors: Andrew Blauvelt, Andrea Chiricozzi, Benjamin D. Ehst

Published in: Current Dermatology Reports | Issue 1/2020

Login to get access

Abstract

Purpose of Review

Bimekizumab, a novel monoclonal antibody directed against both interleukin (IL)-17A and IL-17F, is in clinical development as a treatment for psoriasis and psoriatic arthritis. The purpose of this review is to highlight the roles of IL-17A and IL-17F in psoriatic inflammation as well as the clinical data on bimekizumab that has been reported to date.

Recent Findings

Phase 2 efficacy results with bimekizumab have demonstrated high levels of rapid skin clearance in psoriasis patients, and high levels of joint disease improvement in psoriatic arthritis patients. Thus far, safety concerns have been limited to cases of mucocutaneous candidiasis, which have been mild-to-moderate and manageable in most instances.

Summary

IL-17A and IL-17F are key pro-inflammatory effector cytokines that are over-expressed in psoriatic skin and joints. Bimekizumab, which targets both IL-17A and IL-17F, has shown great promise thus far as a new treatment for patients with psoriasis and psoriatic arthritis. Confirmatory efficacy and safety results in phase 3 studies for these diseases are eagerly anticipated.
Literature
1.
• Ortega C, Fernández AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009;86:435–43 Early characterization of IL-17-producing cells within psoriatic skin. CrossRefPubMed
2.
Hijnen D, Knol EF, Gent YY, Giovannone B, Beijn SJ, Kupper TS, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-g, IL-13, IL-17, and IL-22. J Invest Dermatol. 2013;133:973–9.CrossRefPubMed
3.
• Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–11 Early report distinguishing discrete populations of Th17 and Th1 cells within psoriatic skin. CrossRefPubMed
4.
Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, et al. Overrepresentation of IL-17 and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 2010;5:e14108.CrossRefPubMedPubMedCentral
5.
Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018;19:E179.CrossRefPubMed
6.
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55:379–90 Recent comprehensive review on the roles IL-17 family members play in psoriatic inflammation. CrossRefPubMedPubMedCentral
7.
Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17–26.CrossRefPubMed
8.
Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5:9–19.CrossRefPubMedPubMedCentral
9.
• Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17. J Immunol. 2011;186:1495–502 Established IL-17-mediated cutaneous effects as downstream from IL-23 signaling in skin of mice. CrossRefPubMed
10.
Nakajima K, Kanda T, Takaishi M, Shiga T, Miyoshi K, Nakajima H, et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol. 2011;186:4481–9.CrossRefPubMed
11.
• Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130:1373–83 Extensive characterization of distinct inflammatory T cell subsets in the blood of psoriasis patients.CrossRefPubMed
12.
Chiricozzi A, Cannizzaro MV, Salandri GA, Marinari B, Pitocco R, Dattola A, et al. Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy. J Eur Acad Dermatol Venereol. 2016;30:e128–9.PubMed
13.
Chiricozzi A, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Li K, Tian S, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016;174:136–45.CrossRefPubMed
14.
Suárez-Fariñas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 2012;132:2552–64.CrossRefPubMedPubMedCentral
15.
Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, Nograles KE, Shemer A, Fuentes-Duculan J, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol. 2009;124:1235–1244.e58.CrossRefPubMed
16.
Keijsers RRMC, Hendriks AGM, van Erp PEJ, van Cranenbroek B, van de Kerkhof PCM, Koenen HJPM, et al. In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORgt and IL-17. J Invest Dermatol. 2014;134:1276–84.CrossRefPubMed
17.
Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490–500.CrossRefPubMed
18.
19.
Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ. Responsiveness of serum C-reactive protein, interleukin-17A, and interleukin-17F levels to ustekinumab in psoriatic arthritis: lessons from two phase III, multicenter, double-blind, placebo-controlled trials. Arthritis Rheum. 2019;71:1660–9.CrossRef
20.
Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–94.CrossRefPubMedPubMedCentral
21.
• Chiricozzi A, Nograles KE, Johnson-Huang LM, Fuentes-Duculan J, Cardinale I, Bonifacio KM, et al. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One. 2014;9:e90284 Characterization of IL-17-mediated downstream gene expression in keratinocytes. CrossRefPubMedPubMedCentral
22.
Arakawa A, Siewert K, Stöhr J, Besgen P, Kim SM, Rühl G, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015;212:2203–12.CrossRefPubMedPubMedCentral
23.
Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621.CrossRefPubMed
24.
Nishimoto S, Kotani H, Tsuruta S, Shimizu N, Ito M, Shichita T, et al. Th17 cells carrying TCR recognizing epidermal autoantigen induce psoriasis-like skin inflammation. J Immunol. 2013;191:3065–72.CrossRefPubMed
25.
26.
Fuentes-Duculan J, Bonifacio KM, Hawkes JE, Kunjravia N, Cueto I, Li X, et al. Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes. Exp Dermatol. 2017;26:1075–82.CrossRefPubMedPubMedCentral
27.
• Matos TR, O'Malley JT, Lowry EL, Hamm D, Kirsch IR, Robins HS, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones. J Clin Invest. 2017;127:4031–41 Detailed characterization of IL-17 producing T cells that remain in healed psoriasis skin that are responsible for psoriasis recurrences. CrossRefPubMedPubMedCentral
28.
• Cheuk S, Wikén M, Blomqvist L, Nylén S, Talme T, Ståhle M, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192:3111–20 Initial characterization of Tc17 cells that remain in healed psoriasis skin that are responsible for psoriasis recurrences. CrossRefPubMedPubMedCentral
29.
Gallais Sérézal I, Classon C, Cheuk S, Barrientos-Somarribas M, Wadman E, Martini E, et al. Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome. J Invest Dermatol. 2018;138:1754–63.CrossRefPubMed
30.
Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190:2252–62.CrossRefPubMed
31.
Norsgaard H, Hebsgaard J, Ewald D, Tiirikainen M, Lovato P, Bertelsen M, et al. Multiple IL-17 cytokines, signalling through IL-17 receptor A, drive inflammatory pathways in psoriasis. Poster P1974 presented at the 27th annual European Academy of Dermatology and Venerology (EADV) Congress in Paris, 2018.
32.
• Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol. 2009;182:3112–20 Delineation of biologic effects of IL-17A versus IL-17F in synoviocytes. CrossRefPubMed
33.
Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguier V, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1-α, and TNF-α recapitulates some features of psoriasis. J Immunol. 2010;184:5263–70.CrossRefPubMed
34.
Noack M, Beringer A, Miossec P. Additive or synergistic interactions between IL-17A or IL-17F and TNF or IL-1β depend on the cell type. Front Immunol. 2019;10:1726.CrossRefPubMedPubMedCentral
35.
• Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol. 2009;182:3112–20 Delineation of downstream gene expression induced by IL-17A versus IL-17F in synoviocytes. CrossRefPubMed
36.
• Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677–87 Key description of biologic synergy that occurs with TNF-α and IL-17 within psoriasis. CrossRefPubMed
37.
Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1–induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol. 1998;161:409–14.PubMed
38.
Bonaventura P, Lamboux A, Albarede F, Miossec P. Differential effects of TNF-alpha and IL-1beta on the control of metal metabolism and cadmium-induced cell death in chronic inflammation. PLoS One. 2018;13:e0196285.CrossRefPubMedPubMedCentral
39.
Maroof A, Okoye R, Smallie T, et al. Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of IL-17F contribution to chronic inflammation in disease-relevant cells. Ann Rheum Dis. 2017;76:A1–A103 02.13.
40.
Maroof A, Smallie T, Archer S, Baeten D, Archer S, Simpson C, et al. Dual IL-17A and IL-17F inhibition with bimekizumab provides evidence for IL-17F contribution to immune-mediated inflammatory skin response. J Invest Dermatol. 2017;137:S120.CrossRef
41.
Maroof A, Baeten D, Archer S, Griffiths M, Shaw S. IL-17F contributes to human chronic inflammation in synovial tissue: preclinical evidence with dual IL-17A and IL-17F inhibition with bimekizumab in psoriatic arthritis. Ann Rheum Dis. 2017;76:A13 -A.CrossRef
42.
•• Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, ADG L, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–32 Delineation of in vitro biologic effects of dual blockade of IL-17A/IL-17F versus single blockade of each cytokine alone as well as description of initial clinical study in psoriatic arthritis patients. CrossRefPubMed
43.
•• Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83:991–1001 First-in-human phase 1 study of bimekizumab in psoriasis. CrossRefPubMedPubMedCentral
44.
•• Papp KA, Merola JF, Gottlieb AB, Strimenopoulou F, Price G, Vajjah P, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79:277–286.e10 Phase 2 week 12 results of bimekizumab for psoriasis showing rapid clearing of skin. CrossRefPubMed
45.
•• Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, et al. Dual neutralisation of interleukin (IL)–17A and IL–17F with bimekizumab in moderate-to-severe plaque psoriasis: 60-week results from a randomised, double-blinded, phase 2b extension study. Ann Rheum Dis. 2019;78:1834 Phase 2 week 60 results of bimekizumab for psoriasis showing high levels of skin clearance and durability of responses over time.
46.
•• Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, et al. Dual neutralization of IL-17A and IL-17F with bimekizumab in patients with active PsA: results from a 48-week phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2018;70:10 Phase 2 week 48 efficacy and safety results in psoriatic arthritis patients.
47.
van der Heijde D, Gensler L, Deodhar A, Baraliakos X, Poddubnyy D, Farmer MK, et al. Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2018;77:70.CrossRef
48.
Metadata
Title
Bimekizumab
Authors
Andrew Blauvelt
Andrea Chiricozzi
Benjamin D. Ehst
Publication date
01-03-2020
Publisher
Springer US
Published in
Current Dermatology Reports / Issue 1/2020
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-020-00286-2

Other articles of this Issue 1/2020

Current Dermatology Reports 1/2020 Go to the issue

Photodermatology (B Adler and V DeLeo, Section Editor)

Sunscreen Safety: a Review of Recent Studies on Humans and the Environment

Infectious Disease and Dermatology (C Beard and K. Krishnamurthy, SECTION EDITORS)

Molluscum Contagiosum: Review and Update on Clinical Presentation, Diagnosis, Risk, Prevention, and Treatment

Infectious Disease and Dermatology (C Beard and K. Krishnamurthy, SECTION EDITORS)

Risk, Prevention, Diagnosis, and Management of Cellulitis and Erysipelas

Veterinary Dermatology (A Rostaher and N Fischer, Section Editors)

What Can We Learn from Canine Atopic Dermatitis History?

Psoriasis (J Wu, Section Editor)

Update on Sleep and Pulmonary Comorbidities in Psoriasis

Skin Cancer (E Tongdee and O Markowitz, Section Editors)

Teledermatology for Skin Cancer: The Australian Experience